



IF W

Att. Docket No.: REG 980A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wiegand et al.

Serial No.: 10/758,798

Group: to be assigned

Filing Date: January 16, 2004

Examiner: to be assigned

Title: Methods of Identifying Modulators of NMUR2-Mediated Activity

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner for Patents, United States Patent and Trademark Office, P. O. Box 1450, Alexandria, VA 22313-1450.

Loren Hernandez
Loren Hernandez

October 19, 2004
Date

Commissioner for Patents
US Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449 and copies of references listed therein. The PTO is kindly requested to make of record those references, which may be pertinent to the examination of the above-referenced application.

Att. Docket No.: REG 980A
USSN: 10/758,798
File Date: January 16, 2004
Information Disclosure Statement

This Information Disclosure Statement is being filed:


After three months of the file date of the above referenced application, but before the mailing date of any of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under §1.114.

Accordingly, no fee is required for the submission.

Fees

There is no fee required for the filing of this Information Disclosure Statement. In the event there is a fee inadvertently omitted, Applicants hereby authorizes the fee to be charge to Deposit Account number 18-0650.

Respectfully submitted


Valeta Gregg
Reg. No. 35,127
Attorney for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 980A
 Serial No. : 10/758,798
 Applicant: Wiegand et al.
 Date Filed : January 16, 2004
 For : Methods of Identifying Modulators of
 NMUR2-Mediated Activity

Examiner : to be assigned
 Group Art Unit : to be assigned

Commissioner of Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/Subclass</u>	<u>Filing Date</u>
_____	_____	_____	_____	_____	_____

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/Subclass</u>	<u>Translation Yes</u>	<u>No</u>
_____	GB 2363793A	09 Jan. 2002	Great Britian	_____	_____	_____
_____	WO 01/25269A	12 April 2001	PCT	_____	_____	_____
_____	EP 1237001A	04 Sept. 2002	Europe	_____	_____	_____
_____	WO 01/81418A	01 Nov. 2001	PCT	_____	_____	_____

EP 1365246A 26 Nov. 2003 Europe

OTHER DOCUMENTS

**Examiner
Initials**

Funes, S., et al. (2002) Peptides, Vol. 23, pp. 1607-1615.

Raddatz, R., et al. (2000) J. Biol. Chem., Vol. 275, No. 42, pp. 32452-32459.

Shan, L.X., et al. (2000) J. Biol. Chem., Vol. 275, No. 50, pp. 39482-39486.

Cao, C.Q., et al. (2003) PAIN, Vol. 104, pp. 609-616.


EXAMINER
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:


Valeta Gregg

Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400